| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cathepsin L Inhibitor I targets cathepsin L, a lysosomal cysteine protease that plays a pivotal role in protein turnover, antigen processing, and various cellular signaling pathways. It functions by selectively binding to the active site of cathepsin L, effectively blocking substrate access. It is also an inhibitor of cathepsin B.
|
|---|---|
| ln Vitro |
In vitro, Cathepsin L Inhibitor I is a potent and irreversible inhibitor of cathepsin L. It is cell-permeable. The compound selectively binds to the active site of cathepsin L, altering the enzyme's conformational dynamics and impacting its catalytic efficiency.
|
| ln Vivo |
In vivo activity data for Cathepsin L Inhibitor I are not extensively detailed in the available sources. As a research tool, it is used to study the role of cathepsin L in various physiological and pathological processes. Specific in vivo efficacy data in animal models have not been reported.
|
| Enzyme Assay |
The in vitro enzyme assay for Cathepsin L Inhibitor I involves measuring the inhibition of cathepsin L protease activity. The enzyme is incubated with a fluorogenic substrate in the presence of varying compound concentrations. The reduction in substrate cleavage is measured, and the IC50 is determined.
|
| Cell Assay |
Cellular assays for Cathepsin L Inhibitor I are performed using cell lines. Cells are treated with the compound, and cathepsin L activity is assessed using activity-based probes or by measuring the degradation of specific substrates.
|
| Animal Protocol |
In vivo animal studies for Cathepsin L Inhibitor I are not detailed in the available sources. The compound is a research tool for studying cathepsin L function. Specific animal models, dosing regimens, and efficacy data have not been reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Cathepsin L Inhibitor I are not available in the provided sources. The compound is cell-permeable and is used in biochemical research. Specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicity data for Cathepsin L Inhibitor I are not reported in the available sources. As a research compound, it is not intended for therapeutic use. Specific toxicological profiles have not been characterized.
|
| References |
|
| Additional Infomation |
Cathepsin L Inhibitor I is a research compound for studying cathepsin L function in protein degradation and cellular signaling. It is a potent and irreversible inhibitor. The compound is available from commercial suppliers for research purposes only.
|
| Molecular Formula |
C27H27FN2O4
|
|---|---|
| Molecular Weight |
462.512690782547
|
| Exact Mass |
462.195
|
| CAS # |
108005-94-3
|
| PubChem CID |
16760359
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.572
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CC(C(=O)CF)NC(=O)C(CC2=CC=CC=C2)NC(=O)OCC3=CC=CC=C3
|
| InChi Key |
CAILNONEKASNSH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H27FN2O4/c28-18-25(31)23(16-20-10-4-1-5-11-20)29-26(32)24(17-21-12-6-2-7-13-21)30-27(33)34-19-22-14-8-3-9-15-22/h1-15,23-24H,16-19H2,(H,29,32)(H,30,33)
|
| Chemical Name |
benzyl N-[1-[(4-fluoro-3-oxo-1-phenylbutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~42.5 mg/mL (~91.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.7 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 17.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.7 mg/mL (3.68 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 17.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.7 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1621 mL | 10.8106 mL | 21.6212 mL | |
| 5 mM | 0.4324 mL | 2.1621 mL | 4.3242 mL | |
| 10 mM | 0.2162 mL | 1.0811 mL | 2.1621 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
